Monoclonal antibodies derived from B cells in subjects with cystic fibrosis reduce <i>Pseudomonas aeruginosa</i> burden in mice.

ABSTRACT: Pseudomonas aeruginosa (PA) is an opportunistic, frequently multidrug-resistant pathogen that can cause severe infections in hospitalized patients. Antibodies against the PA virulence factor, PcrV, protect from death and disease in a variety of animal models. However, clinical trials of PcrV-binding antibody-based products have thus far failed to demonstrate benefit. Prior candidates were derivations of antibodies identified using protein-immunized animal systems and required extensive engineering to optimize binding and/or reduce immunogenicity. Of note, PA infections are common in people with cystic fibrosis (pwCF), who are generally believed to mount normal adaptive immune responses. Here we utilized a tetramer reagent to detect and isolate PcrV-specific B cells in pwCF and, via

SUBMITTER: Hale M 

PROVIDER: S-EPMC11030358 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature